These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 26573217)

  • 21. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.
    Anthony K; Feng L; Arechavala-Gomeza V; Guglieri M; Straub V; Bushby K; Cirak S; Morgan J; Muntoni F
    Hum Gene Ther Methods; 2012 Oct; 23(5):336-45. PubMed ID: 23075107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eteplirsen for paediatric patients with Duchenne muscular dystrophy: A pooled-analysis.
    Randeree L; Eslick GD
    J Clin Neurosci; 2018 Mar; 49():1-6. PubMed ID: 29254734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
    Wagner KR; Kuntz NL; Koenig E; East L; Upadhyay S; Han B; Shieh PB
    Muscle Nerve; 2021 Sep; 64(3):285-292. PubMed ID: 34105177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exon skipping therapy for Duchenne muscular dystrophy.
    Kole R; Krieg AM
    Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review.
    Pascual-Morena C; Cavero-Redondo I; Álvarez-Bueno C; Mesas AE; Pozuelo-Carrascosa D; Martínez-Vizcaíno V
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1738-1752. PubMed ID: 33325654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids.
    Goemans N; Tulinius M; Kroksmark AK; Wilson R; van den Hauwe M; Campion G
    Neuromuscul Disord; 2017 Mar; 27(3):203-213. PubMed ID: 28169120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
    Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence JM; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz S
    Muscle Nerve; 2013 Sep; 48(3):343-56. PubMed ID: 23681930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicological Characterization of Exon Skipping Phosphorodiamidate Morpholino Oligomers (PMOs) in Non-human Primates.
    Carver MP; Charleston JS; Shanks C; Zhang J; Mense M; Sharma AK; Kaur H; Sazani P
    J Neuromuscul Dis; 2016 Aug; 3(3):381-393. PubMed ID: 27854228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
    Brogna C; Coratti G; Pane M; Ricotti V; Messina S; D'Amico A; Bruno C; Vita G; Berardinelli A; Mazzone E; Magri F; Ricci F; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Previtali SC; Politano L; Comi GP; Sansone VA; Donati A; Bertini E; Muntoni F; Goemans N; Mercuri E;
    PLoS One; 2019; 14(6):e0218683. PubMed ID: 31237898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP
    J Neuromuscul Dis; 2022; 9(4):493-501. PubMed ID: 35634851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
    Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
    PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
    Guncay A; Yokota T
    Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
    [No Abstract]   [Full Text] [Related]  

  • 37. Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line.
    Dowling JJ
    Nat Rev Neurol; 2016 Dec; 12(12):675-676. PubMed ID: 27857122
    [No Abstract]   [Full Text] [Related]  

  • 38. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
    Rodrigues M; Yokota T
    Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
    Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
    Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
    Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
    Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.